ctDNA Monitoring for Small Cell Lung Cancer: Ready for Prime Time?

被引：5
|
作者：
Pellini, Bruna [1 ,2 ]
Chaudhuri, Aadel A. [1 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA
[2] Univ S Florida, Morsani Coll Med, Dept Oncol Sci, Tampa, FL USA
[3] Washington Univ, Dept Radiat Oncol, Div Canc Biol, Sch Med, St Louis, MO USA
[4] Washington Univ, Div Biol & Biomed Sci, Sch Med, St Louis, MO USA
[5] Washington Univ, Dept Genet, Sch Med, St Louis, MO USA
[6] Washington Univ, Dept Biomed Engn, St Louis, MO USA
[7] Washington Univ, Dept Comp Sci & Engn, St Louis, MO USA
[8] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA
[9] Washington Univ, Sch Med, St Louis, MO USA
[10] Washington Univ, Sch Med, 4511 Forest Pk Ave, St Louis, MO 63108 USA
来源：
CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 12期
关键词：
DISEASE;
D O I：
10.1158/1078-0432.CCR-23-0420
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Small cell lung cancer (SCLC) is the deadliest form of lung cancer and has few precision medicine approaches available. A recent study analyzed circulating tumor DNA (ctDNA) in 33 patients with extensive-stage SCLC and showed that ctDNA levels and response patterns correlate strongly with clinical response and survival outcomes.See related article by Sivapalan et al., p. 2310
引用
收藏
页码：2176 / 2178
页数：3
相关论文
共 50 条
  • [41] In silico cancer modeling: is it ready for prime time?
    Thomas S Deisboeck
    Le Zhang
    Jeongah Yoon
    Jose Costa
    Nature Clinical Practice Oncology, 2009, 6 : 34 - 42
  • [42] Breast Cancer Immunotherapy: Is It Ready for Prime Time?
    Mittendorf, Elizabeth A.
    Hunt, Kelly K.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2015, 11 (09) : 6 - 9
  • [43] Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
    Hassan, Raffit
    Thomas, Anish
    Alewine, Christine
    Le, Dung T.
    Jaffee, Elizabeth M.
    Pastan, Ira
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4171 - +
  • [44] Cancer and diabetes: are we ready for prime time?
    Smith, U.
    Gale, E. A. M.
    DIABETOLOGIA, 2010, 53 (08) : 1541 - 1544
  • [45] Cancer and diabetes: are we ready for prime time?
    U. Smith
    E. A. M. Gale
    Diabetologia, 2010, 53 : 1541 - 1544
  • [46] ARE CANCER STEM CELLS READY FOR PRIME TIME?
    Liu, Suling
    Korkaya, Hasan
    Wicha, Max S.
    SCIENTIST, 2012, 26 (04): : 32 - 37
  • [47] GITR Antibodies in Cancer: Not Ready for Prime Time
    Hernandez-Guerrero, Tatiana
    Moreno, Victor
    CLINICAL CANCER RESEARCH, 2022, 28 (18) : 3905 - 3907
  • [48] Is outcomes research on cancer ready for prime time?
    Clancy, CM
    Lawrence, W
    MEDICAL CARE, 2002, 40 (06) : 92 - 100
  • [49] In silico cancer modeling: is it ready for prime time?
    Deisboeck, Thomas S.
    Zhang, Le
    Yoon, Jeongah
    Costa, Jose
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (01): : 34 - 42
  • [50] Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
    Tomasini, Pascale
    Greillier, Laurent
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S323 - S326
12345